Современные алгоритмы лечения больных лимфомой Ходжкина на ранних стадиях | Український Медичний Часопис

В статье представлен обзор международных исследований по изучению эффективности лечения больных лимфомой Ходжкина на ранних стадиях с применением химио- и лучевой терапии, которые к настоящему времени завершены или продолжаются. Приведены европейские и американские стандарты лечения больных, разработанные на основании данных рандомизированных исследований (категории доказательности І и ІІ).

Ссылки

1. Bonadonna G., Zucali R., Monfardini S. et al. (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer, 36(1): 252–259.
2. Bonadonna G., Bonfante V., Viviani S.et al. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J. Clin. Oncol., 22(14): 2835–2841.
3. Canellos G.P., Niedzwiecki D. (2002) Long-term follow-up of Hodgkin’s disease trial. N. Engl. J. Med., 346(18): 1417–1418.
4. Cheson B.D., Pfistner B., Juweid M.E. et al.; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J. Clin. Oncol., 25(5): 579–586.
5. Carbone P.P., Kaplan H.S., Musshoff K. et al. (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res., 31(11): 1860–1861.
6. Diehl V., Franklin J., Pfreundschuh M. et al. ; German Hodgkin’s Lymphoma Study Group (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N. Engl. J. Med., 348(24): 2386–2395.
7. Duggan D.B., Petroni G.R., Johnson J.L. et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J. Clin. Oncol., 21(4): 607–614.
8. Engert A., Dreilyng M. (2008) Hodgkin’s lymphoma: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol., 19 (suppl 2): ii65–66
9. Engert A., Franklin J., Eich H.T. et al. (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J. Clin. Oncol., 25(223): 3495–3502.
10. Engert A., Schiller P., Josting A. et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J. Clin. Oncol., 21(19): 3601–3608.
11. Ekstrand B.C., Lucas J.B., Horwitz S.M. et al. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of phase 2 trial. Blood, 101(11): 4285–4289.
12. Fermé C, Eghbali H, Hagenbeek A. (2000) MOPP/ABV (M/A) hybrid irradiation in unfavorable supradiaphragmatic clinical stages I–II HD: comparison or three treatment modalities, preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood; 96: 576a (Abstr. 2473).
13. Fermé C., Eghbali H., Meerwaldt J.H. et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N. Engl. J. Med., 357(19): 1916–1927.
14. Glick J.H., Young M.L., Harrington D. et al. (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J. Clin. Oncol., 16(1): 19–26.
15. Hagenbeek A., Eghbali H., Fermé C. et al. (2000) Three cycles of MOPP/ABV M/A hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I–II Hodgkin’s disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood; 96(11): 575a (Abstr. 2472).
16. Henry-Amar M., Friedman S., Hayat M.et al. (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease: the EORTC Lymphoma Cooperative Group. Ann. Intern. Med., 114(5): 361–365.
17. Horning S.J., Hoppe R.T., Breslin S. et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J. Clin. Oncol., 20(3): 630–637.
18. Horning S.J., Hoppe R.T., Advani R. et al. (2004) Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin’s disease: mature data in early and advanced stage patients. Blood, 104: 92а (Abstr. 308).
19. Horning S.J., Hoppe R.T., Advani R.H. et al. (2007) A prospective trial of involved field radiation (IFRT) + chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: survival differences and implications of mature follow-up for current combined modality therapy. J. Clin. Oncol., 25(18 Suppl 1): Abstract 8014.
20. Jones S.E., Haut A., Weick J.K. et al. (1983) Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin’s disease. A Southwest Oncology Group Study. Cancer, 51(8): 1339–1347.
21. Lister T.А., Crowther C., Sutcliffe S.В. et al. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J. Clin. Oncol., 7(11): 1630–1636.
22. Lister T.A., Crowther D. (1990) Staging for Hodgkin’s disease. Semin. Oncol., 17(6): 696–703.
23. Mauch P.V., Armitage J.O., Diehl V. et al. (eds.) (1999) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, PA, p. 223–228.
24. National Comprehensive Cancer Network (2008) NCCN Clinical Practice Guidelines in Oncology. Hodgkin Disease/Lymphoma. V.2.2008 (http://archives.who.int/professionals/physician_gls/PDF/hodgkins.pdf).
25. Noordijk E.M., Carde P., Dupouy N. et al. (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J. Clin. Oncol., 24(19): 3128–3135.
26. Nogová L., Reineke T., Eich H.T. et al. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann. Oncol., 16(10): 1683–1687.
27. Press O.W., LeBlanc M., Lichter A.S. et al. (2001) Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J. Clin. Oncol., 19(22): 4238–4244.
28. Rehwald U., Schulz H., Reiser M. et al. (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 101(2): 420–424.
29. Sieber M., Franklin J., Tesch H. et al. (2002) Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group (GHSG) trial HD7. Blood, 100: 341a.

Сучасні алгоритми лікування хворих із лімфомою Ходжкіна на ранніх стадіях

Крячок Ірина Анатоліївна, Мартинчик А В, Титаренко І Б, Алексик О М, Новосад О І, Кущевий Є В, Каднікова Т В

Резюме. У статті наведено огляд міжнародних досліджень щодо вивчення ефективності лікування хворих із лімфомою Ходжкіна на ранніх стадіях із застосуванням хіміо- та променевої терапії, які на сьогодні завершені або тривають. Наведено європейські й американські стандарти лікування хворих, розроблені на підставі даних рандомізованих досліджень (категорії доказовості I і II).

Ключові слова:лімфома Ходжкіна, хіміотерапія, променева терапія, стандарти лікування

Modern algorithms of treatment of patients with early stage Hodgkin’s lymphoma

Kryachok I A, Martynchyk A V, Titarenko I B, Aleksik E M, Novosad O I, Kushchevoj E V, Kadnikova T V

Summary. The review presents the international studies concerning efficiency of early stage Hodgkin’s lymphoma treatment with use of chemotherapy and radiotherapy that have been completed or are still in progress. The European and American standards of Hodgkin’s disease treatment developed on the basis of the randomized trials data (categories І–ІІ evidence) are submitted.

Key words: Hodgkin’s lymphoma, chemotherapy, radiotherapy, standards of treatment